Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase I/IB Open-Label, Dose-Escalation Study of APVO436 in Patients With Relapsed or Refractory AML or High-Grade MDS
A Randomized, Open-Label, Phase I/II Study of ASTX727 Low Dose ASTX727 LD Extended Schedule in Subjects with Lower Risk IPSS Low or Intermediate-1 Myelodysplastic Syndromes MDS
Phase IIIb, Open-label study evaluating the efficacy and safety of luspatercept BMS-986346/ACE-536 initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions MAXILUS
Study Type: Treatment
Phase: III
NCTID: NCT06045689
Principal Investigator:
Jesus Gonzalez Lugo
Venetoclax In Combination with ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts VICTORY-MDS/MPN: a Randomized, Phase II trial
A Phase I/II, Dose-Escalation Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia AML and Myelodysplasia-Excess Blasts MDS-EB
A Phase II trial of Pevonedistat and Azacitidine in MDS or MDS/MPN patients who fail primary therapy with DNA methyl transferase inhibitors
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor MUD versus HLA-Haploidentical Related Haplo Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults AYA with Acute Leukemia or Myelodysplastic Syndrome MDS
Study Type: Treatment
Phase: III
NCTID: NCT05457556
Principal Investigator:
Ibrahim Ahmed
A First-in-Human FIH, Phase 1, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Refractory or Relapsed Acute Myeloid Leukemia R/R AML or Refractory or Relapsed Higher-risk Myelodysplastic Syndromes R/R HR-MDS
Study Type: Treatment
Phase: I
NCTID: NCT06146257
Principal Investigator:
Jesus Gonzalez Lugo
A Phase IIA, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 a Liposomal Grb2 Antisense Oligonucleotide in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia AML Who Are Ineligible for Intensive Induction Therapy
Randomized Phase II Study of daunorubicin and cytarabine liposome + Pomalidomide versus daunorubicin and cytarabine liposome in Newly Diagnosed AML with MDS-Related Changes.
Study Type: Treatment
Phase: II
NCTID: NCT04802161
Principal Investigator:
Jesus Gonzalez Lugo